NVAX Novavax Inc
Price (delayed)
$5.98
Market cap
$961.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$651.41M
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III
Highlights
Novavax's EPS has surged by 77% YoY and by 44% QoQ
NVAX's quick ratio has surged by 67% year-on-year and by 4.7% since the previous quarter
Novavax's equity has decreased by 19% QoQ but it has increased by 13% YoY
The revenue has contracted by 31% YoY and by 23% from the previous quarter
NVAX's gross profit is down by 25% YoY and by 15% QoQ
Key stats
What are the main financial stats of NVAX
Market
Valuations
Earnings
Shares outstanding
160.84M
Market cap
$961.85M
Enterprise value
$651.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.95
Revenue
$682.16M
Gross profit
$479.42M
Operating income
-$248.93M
Net income
-$187.5M
EBIT
-$156.54M
EBITDA
-$108.04M
Free cash flow
-$101.9M
Per share
Balance sheet
Liquidity
EPS
-$1.23
EPS diluted
-$1.23
Free cash flow per share
-$0.67
Book value per share
-$3.89
Revenue per share
$4.48
TBVPS
$9.55
Total assets
$1.56B
Total liabilities
$2.18B
Debt
$230.42M
Equity
-$623.84M
Working capital
-$25.47M
Debt to equity
-0.37
Current ratio
0.98
Quick ratio
0.9
Net debt/EBITDA
2.87
Margins
Efficiency
Dividend
EBITDA margin
-15.8%
Gross margin
70.3%
Net margin
-27.5%
Operating margin
-36.5%
Return on assets
-11.6%
Return on equity
N/A
Return on invested capital
-218.7%
Return on capital employed
-38.6%
Return on sales
-22.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVAX stock price
How has the Novavax stock price performed over time
Intraday
-0.33%
1 week
-19.08%
1 month
-28.21%
1 year
32.01%
YTD
-25.62%
QTD
-6.71%
Financial performance
How have Novavax's revenue and profit performed over time
Revenue
$682.16M
Gross profit
$479.42M
Operating income
-$248.93M
Net income
-$187.5M
Gross margin
70.3%
Net margin
-27.5%
Novavax's net income has soared by 66% YoY and by 34% from the previous quarter
Novavax's operating income has soared by 56% YoY and by 17% from the previous quarter
Novavax's net margin has surged by 50% YoY and by 15% QoQ
The operating margin has increased by 37% year-on-year but it has declined by 7% since the previous quarter
Growth
What is Novavax's growth rate over time
Valuation
What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
1.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.95
Novavax's EPS has surged by 77% YoY and by 44% QoQ
Novavax's equity has decreased by 19% QoQ but it has increased by 13% YoY
NVAX's P/S is 88% below its 5-year quarterly average of 11.1 and 21% below its last 4 quarters average of 1.7
The revenue has contracted by 31% YoY and by 23% from the previous quarter
Efficiency
How efficient is Novavax business performance
NVAX's return on assets has surged by 64% year-on-year and by 32% since the previous quarter
Novavax's return on sales has surged by 57% YoY and by 23% QoQ
Dividends
What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVAX.
Financial health
How did Novavax financials performed over time
Novavax's total assets is 29% lower than its total liabilities
NVAX's quick ratio has surged by 67% year-on-year and by 4.7% since the previous quarter
The current ratio has increased by 40% year-on-year and by 5% since the previous quarter
Novavax's debt is 137% higher than its equity
Novavax's equity has decreased by 19% QoQ but it has increased by 13% YoY
NVAX's debt to equity is up by 16% since the previous quarter but it is down by 16% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.